RT Journal
A1 Kuehn BM
T1 FDa requires black box warnings on labeling for botulinum toxin products
JF JAMA
JO JAMA
YR 2009
FD June 10
VO 301
IS 22
SP 2316
OP 2316
DO 10.1001/jama.2009.780
UL http://dx.doi.org/10.1001/jama.2009.780
AB 
The FDA is also requiring Allergan Inc, which sells Botox and Botox Cosmetic (botulinum toxin type A); Solstice Neurosciences Inc, which sells Myobloc (botulinum toxin type B); and Ipsen Biopharm Ltd, maker of the recently FDA-approved Dysport (abobotulinumtoxinA), to develop risk-management strategies plans to prevent such adverse events. Additionally, the agency is requiring clinicians to provide a medication guide outlining botulismlike risks to patients treated with the drug or to their caregivers.